TRADIPITANT, A NOVEL NEUROKININ-1 RECEPTOR ANTAGONIST, SHOWED CONTINUED IMPROVEMENT IN NAUSEA AND OTHER SYMPTOMS ASSOCIATED WITH GASTROPARESIS IN AN OPEN-LABEL EXTENSION OF A PHASE II CLINICAL TRIAL
Jesse L. Carlin 1
1 Vanda Pharmaceuticals, Inc.
Topic
Histopathology, IBD, Neurogastroenterology & Motility
Conference
UEG Week Virtual 2021
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]
New to myUEG?
Social Sharing